title: [Morphologic characteristic of chronic toxic hepatitis for treatment with Neoselen].
abstract: The purpose of the given research work was to study the features of morphologic changes arising for treatment of chronic hepatitis with Neoselen. It was established a picture of chronic active hepatitis in the liver of rats with the following development of chronic persisting hepatitis by the 40 daily administration of heliotrine and its transmission into cirrhosis in a certain part of animals. Hepatic cirrhosis has a small nodal portal character by its pathognomonic morphologic signs. A noticeable remittance of destructive necrotic changes in hepatic parenchymatous elements and reduction in a volume of proliferative inflammatory infiltration with an acceleration in process of its fibrozation in only periportal zones of hepatic lobules found to be for treatment of chronic hepatitis with Neoselen. That prevents from transmission of chronic hepatitis into cirrhosis in a greater part of animals that is a morphologic evidence of importance of selenium in a restorative process of biologic membranes and its involvement in a remittance process of destructive and inflammatory changes in the liver and prevention from development of agressive hepatitis and its transmission into cirrhosis.
authors.forename: R I
authors.initials: RI
authors.lastname: Isroilov
authors.forename: U Sh
authors.initials: USh
authors.lastname: Salikhodzhaeva
mesh_terms: D000818:Animals; D056487:Chemical and Drug Induced Liver Injury, Chronic / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D004801:Eosine Yellowish-(YS) / Q000032:analysis; D006416:Hematoxylin / Q000032:analysis; D006651:Histocytochemistry; D007249:Inflammation / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D008297:Male; D008867:Microtomy; D009252:NADPH Dehydrogenase / Q000032:analysis / Q000378:metabolism; D011763:Pyrrolizidine Alkaloids / Q000008:administration & dosage / Q000009:adverse effects; D051381:Rats; D018036:Selenium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D011763:Pyrrolizidine Alkaloids; D018036:Selenium Compounds; D009252:NADPH Dehydrogenase; D004801:Eosine Yellowish-(YS); D006416:Hematoxylin; C010178:heliotrine